15599-52-7

Basic information

• Product Name: broquinaldol
• Synonyms: broquinaldol;5,7-DIBROMO-2-METHYL-8-QUINOLINOL, 97%;2-Methyl-5,7-dibromoquinoline-8-ol;5,7-Dibrom-2-methyl-8-chinolinol;Brochinaldol;Broquinaldolum;Broquinaldolum [inn-latin];Broquinaldolum [latin]
• CAS NO: 15599-52-7
• Molecular Formula: C₁₀H₇Br₂NO
• Molecular Weight: 316.97668
• EINECS: 239-680-0
• Mol File: 15599-52-7.mol
• Article Data: 19

Chemical Properties

• Melting Point: 126-130 °C(lit.)
• Boiling Point: 367.4 °C at 760 mmHg
• Flash Point: 176 °C
• Appearance: /
• Density: 1.934 g/cm³
• Vapor Pressure: 6.49E-06mmHg at 25°C
• Refractive Index: 1.713
• CAS DataBase Reference: broquinaldol(CAS DataBase Reference)
• NIST Chemistry Reference: broquinaldol(15599-52-7)
• EPA Substance Registry System: broquinaldol(15599-52-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• Hazardous Substances Data: 15599-52-7(Hazardous Substances Data)

Usage

General Description

Broquinaldol is a chemical compound that belongs to the family of quinoline alkaloids. It is a naturally occurring substance found in certain plants and has been isolated from the bark and leaves of several species. Broquinaldol has been found to possess various biological activities, including antifungal, antibacterial, and antimalarial properties. It has also been studied for its potential use in treating cancer due to its ability to inhibit the growth of cancer cells. Additionally, broquinaldol has shown promise as an anti-inflammatory agent and may have applications in the development of new pharmaceutical drugs. Overall, broquinaldol is a versatile chemical compound with potential benefits for various medical and agricultural applications.

InChI:InChI=1/C10H7Br2NO/c1-5-2-3-6-7(11)4-8(12)10(14)9(6)13-5/h2-4,14H,1H3

Upstream product

• 826-81-3 2-methyl-8-quinolinol 
• 77-48-5 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione 
• 95-55-6 2-amino-phenol 
• 42123-33-1 3-hydroxy-2-nitrobenzaldehyde 
• 100-83-4 meta-hydroxybenzaldehyde 
• 1004545-97-4 2-amino-3-hydroxybenzaldehyde 
• 90-04-0 2-methoxy-phenylamine 
• 40925-68-6 2-amino-4-bromo-phenol 
• 7693-52-9 4-bromo-2-nitrophenol 
• 103862-55-1 5-bromo-8-methoxy-2-methylquinoline 
• 3033-80-5 8-methoxy-2-methylquinoline 
• 23051-08-3 8-hydroxy-2-methylquinoline-7-carboxylic acid 
• 24263-94-3 5-bromo-8-hydroxy-2-methylquinoline 

Downstream Products

• 193351-73-4 (2-Me-5,7-Br₂-8-quinolato)2Zr(CH₂Ph)2 
• 1227180-26-8 5,7-dibromo-2-methylquinolin-8-yl tert-butyl(phenyl)posphinate 
• 1392445-04-3 2-methyl-6-(4-hydroxybiphenyl-4'-ylamino)quinoline-5,8-dione 
• 1392444-96-0 6-(4-hydroxybiphenyl-4'-ylamino)-7-bromo-2-methylquinoline-5,8-dione 
• 1392445-01-0 2-methyl-6-(4-phenylpiperazin-1-yl)quinoline-5,8-dione 
• 1392444-93-7 7-bromo-2-methyl-6-(4-phenylpiperazin-1-yl)quinoline-5,8-dione 
• 1392445-02-1 2-methyl-6-(4-propyl-biphenyl-4'-ylamino)quinoline-5,8-dione 

Relevant articles and documents

New aryloxy-quinone derivatives as potential anti-Chagasic agents: synthesis, trypanosomicidal activity, electrochemical properties, pharmacophore elucidation and 3D-QSAR analysis

A set of new aryloxy-quinones were synthesized and evaluated in vitro against the epimastigote form of Trypanosoma cruzi and their unspecific cytotoxicity was tested on murine macrophages J-774 cells. Most of these novel compounds were found to be much more potent and selective than the standard drug nifurtimox. Interestingly, 2-phenoxy-naphthoquinone 3b displayed a remarkable nanomolar inhibitory activity, IC50 = 20 nM, and a high selectivity index, SI = 625. The Epc1 was determined for the most interesting compounds and no correlation with the trypanosomicidal effect was found. Therefore, an in silico study was carried out to obtain a pharmacophoric model and quantitative structure-trypanosomicidal activity relationship. The designed pharmacophore recognized the more potent and selective molecules, exhibiting five pharmacophoric features. A correlation coefficient R2 of 0.99 of pIC50 plotted against the predicted values indicated that the 3D-QSAR equation could be applied to further predictions of newly designed trypanosomicidal compounds.

Discovery of quinoline small molecules with potent dispersal activity against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis biofilms using a scaffold hopping strategy

Staphylococcus aureus and Staphylococcus epidermidis are recognized as the most frequent cause of biofilm-associated nosocomial and indwelling medical device infections. Biofilm-associated infections are known to be highly resistant to our current arsenal of clinically used antibiotics and antibacterial agents. To exacerbate this problem, no therapeutic option exists that targets biofilm-dependent machinery critical to Staphylococcal biofilm formation and maintenance. Here, we describe the discovery of a series of quinoline small molecules that demonstrate potent biofilm dispersal activity against methicillin-resistant S. aureus and S. epidermidis using a scaffold hopping strategy. This interesting class of quinolines also has select synthetic analogues that demonstrate potent antibacterial activity and biofilm inhibition against S. aureus and S. epidermidis.

Low-toxicity rare earth coordination compounds, preparation method and applications thereof

The invention discloses two low-toxicity rare earth coordination compounds, a preparation method and applications thereof, wherein the two coordination compounds are respectively a coordination compound 1 or a coordination compound 2, the molecular formula of the coordination compound 1 is [Eu(C10H6NOBr2)3(H2O)], and the molecular formula of the coordination compound 2 is [Gd(C10H6NOBr2)3(H2O)]. The preparation method comprises the following steps: taking 2-methyl-5,7-dibromo-8-hydroxyquinoline and europium nitrate hexahydrate or gadolinium nitrate hexahydrate, dissolving with a mixed solvent,adjusting the pH value of the obtained solution to 6.5-8.1, and reacting the obtained mixed solution under a heating condition to obtain a corresponding target product. The test results show that thetwo rare earth coordination compounds have significant inhibitory activity (the inhibitory activity is significantly higher than the inhibitory activity of cis-platinum) on tumor cell strains, have low toxicity on normal hepatocytes, and are expected to be developed into antitumor drugs.

To 2 - methyl - 5, 7 - dibromo -8 - hydroxy quinoline as ligands of the single nucleus arrowhead complex and its preparation method and application

The invention discloses a mononuclear dysprosium complex using 2-methyl-5,7-dibromo-8-hydroxyquinoline as a ligand and a preparation method and application thereof. A chemical formula of the complex is: [Dy(L)3(HL)], wherein L represents a product obtained after hydrogen atom of hydroxyl is removed from 2-methyl-5,7-dibromo-8-hydroxyquinoline, and has one unit of negative charges; HL represents 2-methyl-5,7-dibromo-8-hydroxyquinoline; the complex belongs to a triclinic system and a P-1 space group. The preparation method of the complex, which is disclosed by the invention, comprises: taking Dy(NO3)3.6H2O and 2-methyl-5,7-dibromo-8-hydroxyquinoline; dissolving Dy(NO3)3.6H2O and 2-methyl-5,7-dibromo-8-hydroxyquinoline with methanol; regulating pH of the obtained solution into a range of 6.0 to 7.5; performing a reaction on the obtained mixed solution under the heating condition to obtain the mononuclear dysprosium complex. The complex provided by the invention is simple in preparation method, low in cost and good in repeatability, shows a field-induced slow relaxation magnetic behavior at a low temperature, and can be used for preparing a magnetic material.